Inhibrx says FDA accepts ozekibart BLA for conventional chondrosarcoma treatment
Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. INBX | 0.00 |
- FDA accepted Inhibrx’s BLA for ozekibart to treat unresectable or metastatic conventional chondrosarcoma.
- PDUFA action date set for April 14, 2027; FDA flagged no filing review issues.
- BLA backed by ChonDRAgon trial showing 52% lower risk of progression or death; median PFS 5.52 months vs 2.66 months.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606150915PR_NEWS_USPR_____LA83341) on June 15, 2026, and is solely responsible for the information contained therein.